REG-BARCLAYS PLC Form 8.3 - WILLIS TOWERS WATSON PLC - Amendment
20/07/2021 14:35
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210720:nBwc9l0wxa&default-theme=true
Form 8.3 - WILLIS TOWERS WATSON PLC - Amendment
Ap19
FORM 8.3 - Amendment to Purchases & Sales
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR
MORE
1. KEY INFORMATION
Name of person dealing (Note 1) Barclays PLC.
Company dealt in WILLIS TOWERS WATSON PLC
Class of relevant security to which the ORD
dealings being disclosed relate (Note 2)
Date of dealing 16 July 2021
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security dealt in (Note 3)
Class of relevant security: ORD
Long Short
Number (%) Number (%)
(1) Relevant securities
1,892,713 1.47% 240,773 0.19%
(2) Derivatives (other than options):
1,359 0.00% 158,150 0.12%
(3) Options and agreements to
purchase/sell: 6,100 0.00% 6,100 0.00%
TOTAL:
1,900,172 1.47% 405,023 0.31%
(b) Interests and short positions in relevant securities of the company, other
than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
Purchase 13 222.1492 USD
Purchase 20 221.4400 USD
Purchase 45 221.8700 USD
Purchase 76 222.2400 USD
Purchase 92 222.1300 USD
Purchase 99 221.8900 USD
Purchase 100 223.1383 USD
Purchase 100 222.0500 USD
Purchase 230 221.7332 USD
Purchase 264 222.1637 USD
Purchase 272 221.5638 USD
Purchase 280 222.2900 USD
Purchase 349 221.8907 USD
Purchase 762 222.3245 USD
Purchase 953 222.3394 USD
Purchase 960 221.6355 USD
Purchase 1,245 221.9662 USD
Purchase 1,333 222.4935 USD
Purchase 1,680 221.8260 USD
Purchase 1,766 222.8248 USD
Purchase 1,857 221.8395 USD
Purchase 2,206 222.3018 USD
Purchase 2,751 222.6754 USD
Purchase 2,972 222.3600 USD
Purchase 3,208 221.9241 USD
Purchase 3,208 222.6663 USD
Purchase 3,851 222.4435 USD
Purchase 5,283 222.4936 USD
Purchase 6,000 220.0000 USD
Sale 5 222.2800 USD
Sale 6 221.9700 USD
Sale 22 223.3100 USD
Sale 22 221.8272 USD
Sale 100 222.0200 USD
Sale 100 221.7800 USD
Sale 100 222.9200 USD
Sale 120 221.7840 USD
Sale 186 222.7713 USD
Sale 320 222.0962 USD
Sale 380 222.2900 USD
Sale 618 222.3664 USD
Sale 953 222.3394 USD
Sale 961 222.3600 USD
Sale 1,026 222.2831 USD
Sale 1,796 222.4245 USD
Sale 1,915 222.3497 USD
Sale 2,200 222.4789 USD
Sale 2,206 222.3018 USD
Sale 2,451 222.7410 USD
Sale 4,609 222.6126 USD
Sale 5,881 222.6165 USD
Sale 10,000 221.8551 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
e.g. call option
(ii) Exercising
Product name, Number of securities Exercise price per unit (Note 5)
e.g. call option
(d) Other dealings (including transactions in respect of new securities) (Note
4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
None
Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 20 Jul 2021
Contact name: Large Holdings Regulatory Operations
Telephone number: 020 3134 7213
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or
Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product name Written or Number of Exercise Type Expiry
purchased relevant securities price date
to which the option
or derivative
relates
Put Options Purchased -100 220.0000 American Jul 16, 2021
Call Options Purchased 100 240.0000 American Jul 16, 2021
Call Options Purchased 6,000 220.0000 American Jul 16, 2021
Put Options Purchased -6,000 200.0000 American Jul 16, 2021
Notes
1. Where there are open option positions or open derivative positions (except
for CFDs), full details should be given. Full details of any existing
agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in
doubt, consult the Panel.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20210720005803/en/
(https://www.businesswire.com/news/home/20210720005803/en/)
BARCLAYS PLC
Copyright Business Wire 2021Recent news on Barclays
See all newsREG - Barclays PLC - Transaction in Own Shares
AnnouncementREG - Barclays PLC Greencore Group PLC - Form 8.3 GREENCORE GROUP PLC
AnnouncementREG - Barclays PLC Intnl Personal Fin - Form 8.3 INTERNATIONAL PERSONAL FINANCE PLC
AnnouncementREG - Barclays PLC Just Group plc - Form 8.3 JUST GROUP PLC
AnnouncementREG - Barclays PLC Spire Healthcare Grp - Form 8.3 SPIRE HEALTHCARE GROUP PLC
Announcement